Therapeutic Potential of Ranibizumab in Corneal Neovascularization

descriptionPublicationkeyboard_double_arrow_right Article 01 Aug 2017 English Publisher:Elsevier BVJournal:Trends in Pharmacological Sciences, volume 38, pages 667-668 (issn: 0165-6147,

Copyright policy )

Authors: Marianne L, Shahsuvaryan;

doi: 10.1016/j.tips.2017.05.004

pmid: 28606479

Therapeutic Potential of Ranibizumab in Corneal Neovascularization

- Summary
- Subjects
- Metrics

Abstract

Ranibizumab is a humanized, affinity-matured vascular endothelial growth factor (VEGF) antibody fragment that neutralizes all isoforms of VEGF and is FDA approved for use in ophthalmology. Recently it was suggested that ranibizumab may be useful in the treatment of corneal neovascularization, but in reality this therapy is not yet evidence based.

Related Organizations

Yerevan State Medical University
Armenia

Keywords

Vascular Endothelial Growth Factor A, Ranibizumab, Humans, Angiogenesis Inhibitors, Corneal Neovascularization, Randomized Controlled Trials as Topic

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	12
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%